K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · AMGEN INC.
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-22 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $10K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2026-04-20 | AMGN | AMGEN INC. | TODD STRATEGY GROUP | $80K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy. |
| 2026-04-20 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas |
| 2026-04-20 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals. Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars. Tax issues related to the pharmaceutical industry. Implementation of PL 119-21. Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections. |
| 2026-04-20 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2026-04-18 | AMGN | AMGEN INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to health access. PBM reform. Most-Favored-Nation pricing for pharmaceuticals. 340B. |
| 2026-04-18 | AMGN | AMGEN INC. | CAPITOL COUNSEL LLC | $50K | Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. 340B Program issues. |
| 2026-04-17 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $8K | issues related to pharmaceutical drugs |
| 2026-04-13 | AMGN | AMGEN INC. | HILLNORTH LLC | $38K | Issues related to the pharmaceutical industry. |
| 2026-04-10 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $0 | |
| 2026-03-12 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $8K | issues related to pharmaceutical drugs |
| 2026-03-09 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $8K | issues related to pharmaceutical drugs |
| 2026-01-26 | AMGN | AMGEN INC. | FEDERAL HEALTH COUNSEL, LLC | $0 | Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs. |
| 2026-01-20 | AMGN | AMGEN INC. | TODD STRATEGY GROUP | $80K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy. |
| 2026-01-20 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas |
| 2026-01-20 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals. Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars. Tax issues related to the pharmaceutical industry. Implementation of PL 119-21. Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections. |
| 2026-01-20 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2026-01-20 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | |
| 2026-01-19 | AMGN | AMGEN INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to health access. PBM reform. Most-Favored-Nation pricing for pharmaceuticals. |
| 2026-01-19 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $20K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2026-01-18 | AMGN | AMGEN INC. | CAPITOL COUNSEL LLC | $50K | Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. |
| 2026-01-16 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $8K | issues related to pharmaceutical drugs |
| 2026-01-12 | AMGN | AMGEN INC. | HILLNORTH LLC | $38K | Issues related to the pharmaceutical industry. |
| 2025-11-12 | AMGN | AMGEN INC. | FEDERAL HEALTH COUNSEL, LLC | $0 | Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs. |
| 2025-10-20 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas |
| 2025-10-20 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals. Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars. Tax issues related to the pharmaceutical industry. H.R. 1, "One Big Beautiful Bill Act". Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections. |
| 2025-10-20 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2025-10-20 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $8K | issues related to pharmaceutical drugs |
| 2025-10-19 | AMGN | AMGEN INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to PBM reform. |
| 2025-10-19 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | |
| 2025-10-17 | AMGN | AMGEN INC. | CAPITOL COUNSEL LLC | $50K | Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. |
| 2025-10-14 | AMGN | AMGEN INC. | HILLNORTH LLC | $38K | Issues related to the pharmaceutical industry. |
| 2025-10-14 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $15K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2025-10-11 | AMGN | AMGEN INC. | TODD STRATEGY GROUP | $80K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy. |
| 2025-09-25 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $8K | issues related to pharmaceutical drugs |
| 2025-07-21 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars |
| 2025-07-21 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2025-07-21 | AMGN | AMGEN INC. | CAPITOL COUNSEL LLC | $50K | Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. |
| 2025-07-21 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $15K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2025-07-20 | AMGN | AMGEN INC. | FEDERAL HEALTH COUNSEL, LLC | $0 | Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs. |
| 2025-07-19 | AMGN | AMGEN INC. | TODD STRATEGY GROUP | $80K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy. |
| 2025-07-19 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | |
| 2025-07-18 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | Issues related to patent protections. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health. Pharmacy benefit manager reform proposals. General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act". Tax issues related to the pharmaceutical industry. H.R. 1, "One Big Beautiful Bill Act". Policies impacting disease prevention. Issues related to antitrust legislation. |
| 2025-07-18 | AMGN | AMGEN INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to PBM reform. |
| 2025-07-17 | AMGN | AMGEN INC. | HILLNORTH LLC | $35K | Issues related to the pharmaceutical industry. |
| 2025-07-14 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $8K | issues related to pharmaceutical drugs |
| 2025-04-21 | AMGN | AMGEN INC. | TODD STRATEGY GROUP | $80K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy. |
| 2025-04-21 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health. Pharmacy benefit manager reform proposals. General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Pharmacy benefit manager reform proposals. Tax issues related to the pharmaceutical industry. Policies impacting disease prevention. Issues related to antitrust legislation Issues related to patent protections. |
| 2025-04-21 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas |
| 2025-04-21 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2025-04-21 | AMGN | AMGEN INC. | FEDERAL HEALTH COUNSEL, LLC | $0 | Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid rebate and best price. |
| 2025-04-20 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $10K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2025-04-18 | AMGN | AMGEN INC. | CAPITOL COUNSEL LLC | $50K | Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. |
| 2025-04-18 | AMGN | AMGEN INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to PBM reform; 340B and biosimilars. |
| 2025-04-17 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169). |
| 2025-04-15 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $8K | issues related to pharmaceutical drugs |
| 2025-04-11 | AMGN | AMGEN INC. | HILLNORTH LLC | $30K | Issues related to the pharmaceutical industry. |
| 2025-01-31 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $0 | Educating members on issues impacting Amgen and patients |
| 2025-01-22 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health. General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Tax issues related to the pharmaceutical industry. Policies impacting disease prevention. Issues related to antitrust legislation Issues related to patent protections. |
| 2025-01-22 | AMGN | AMGEN INC. | FEDERAL HEALTH COUNSEL, LLC | $0 | Issues relating to the implementation of Medicare Drug Negotiations and the calculation of Medicaid best price. |
| 2025-01-21 | AMGN | AMGEN INC. | RICCHETTI INCORPORATED | $60K | Issues related to drug pricing and access, Medicare and Medicaid reimbursement; Issues relating to the Medicaid drug rebate program proposed rule Issues related to pharmaceutical industry, generally; Drug pricing and access, and Medicare and Medicaid reimbursement |
| 2025-01-21 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas |
| 2025-01-20 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169). |
| 2025-01-20 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2025-01-20 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $20K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |